Literature DB >> 16435074

A misquoted mutation in exon16 of the BRCA2 gene.

Agapi Kataki1, Anastasia Derventzi2, Ilias Gomatos2, Manoussos M Konstadoulakis2.   

Abstract

A pathogenic mutation in the BRCA2 gene, nt7602del16, has been misquoted as a mutation, possibly due to the incorrect inclusion of the last 16 nucleotides of exon15 of the BRCA2 gene as part of the intron15-exon16 BRCA2 gene sequence in publicly available databases. This was concluded following mutational screening by sequencing and enzymatic mapping of the BRCA2 gene exon15-exon16 region in DNA from peripheral blood samples from a total of 74 breast cancer and non-breast cancer patients as well as healthy individuals and the cell line MCF7. Careful interpretation of genetic variants and direct feedback to the corresponding sequence databases prevent systemic errors by integrating updated data into broadly referenced sources.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16435074     DOI: 10.1007/s10038-005-0347-4

Source DB:  PubMed          Journal:  J Hum Genet        ISSN: 1434-5161            Impact factor:   3.172


  8 in total

1.  Expression of BRCA1 and BRCA2 in different tumor cell lines with various growth status.

Authors:  Cécile Vissac; Monique Peffault De Latour; Yves Communal; Yves-Jean Bignon; Dominique J Bernard-Gallon
Journal:  Clin Chim Acta       Date:  2002-06       Impact factor: 3.786

Review 2.  DNA recombination, chromosomal stability and carcinogenesis: insights into the role of BRCA2.

Authors:  Mahmud K K Shivji; Ashok R Venkitaraman
Journal:  DNA Repair (Amst)       Date:  2004 Aug-Sep

3.  Adjusting the estimated proportion of breast cancer cases associated with BRCA1 and BRCA2 mutations: public health implications.

Authors:  Monica R McClain; Glenn E Palomaki; Katherine L Nathanson; James E Haddow
Journal:  Genet Med       Date:  2005-01       Impact factor: 8.822

4.  BRCA2 gene mutations in Greek patients with familial breast cancer.

Authors:  Athanasios Armakolas; Angela Ladopoulou; Irene Konstantopoulou; B Pararas; Ilias P Gomatos; Agapi Kataki; Manoussos M Konstadoulakis; George P Stathopoulos; Christopher Markopoulos; Emmanouil Leandros; Ioannis Gogas; Drakoulis Yannoukakos; George Androulakis
Journal:  Hum Mutat       Date:  2002-01       Impact factor: 4.878

5.  High proportion of missense mutations of the BRCA1 and BRCA2 genes in Japanese breast cancer families.

Authors:  T Katagiri; F Kasumi; M Yoshimoto; T Nomizu; K Asaishi; R Abe; A Tsuchiya; M Sugano; S Takai; M Yoneda; T Fukutomi; K Nanba; M Makita; H Okazaki; K Hirata; M Okazaki; Y Furutsuma; Y Morishita; Y Iino; T Karino; H Ayabe; S Hara; T Kajiwara; S Houga; Y Miki
Journal:  J Hum Genet       Date:  1998       Impact factor: 3.172

6.  Identification of germline BRCA1 and BRCA2 genetic alterations in Greek breast cancer moderate-risk and low-risk individuals--correlation with clinicopathological data.

Authors:  A Kataki; Ip Gomatos; N Pararas; A Armakolas; D Panousopoulos; G Karantzikos; D Voros; G Zografos; C Markopoulos; E Leandros; Mm Konstadoulakis
Journal:  Clin Genet       Date:  2005-04       Impact factor: 4.438

7.  The breast cancer information core: database design, structure, and scope.

Authors:  C Szabo; A Masiello; J F Ryan; L C Brody
Journal:  Hum Mutat       Date:  2000       Impact factor: 4.878

8.  Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group.

Authors:  Timothy R Rebbeck; Tara Friebel; Henry T Lynch; Susan L Neuhausen; Laura van 't Veer; Judy E Garber; Gareth R Evans; Steven A Narod; Claudine Isaacs; Ellen Matloff; Mary B Daly; Olufunmilayo I Olopade; Barbara L Weber
Journal:  J Clin Oncol       Date:  2004-02-23       Impact factor: 44.544

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.